Lurbinectedin shows potential as second-line treatment for patients with SCLC

Lurbinectedin can potentially be used as a second-line treatment for patients with small-cell lung cancer (SCLC), according to results from a phase 2 published in the Lancet Oncology.

In this single-arm, open-label, phase 2 basket trial, 105 patients with SCLC previous treated with 1 type of chemotherapy at least 3 weeks before the study began, were treated with 3.2 mg/m2 lurbinectedin administered intravenously every 3 weeks until disease progression or unacceptable toxicity. Median follow-up was 17.1 months.

Overall response (complete or partial response) was reported in 35.2% of patients (n = 37). Grade 3-4 adverse events included anaemia (n = 9), leucopenia (n = 30), neutropenia n = 48), and thrombocytopenia (n = 7).

Serious treatment-related adverse events (n = 11) included neutropenia (n =5) and febrile neutropenia (n = 5).

Reference

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645‐654. doi:10.1016/S1470-2045(20)30068-1